In search of the most suitable lentiviral shRNA system

Current Gene Therapy

Volumn 9, Issue 3, 2009, Pages 192-211

  Bos, Tomas Jan ^a   De Bruyne, Elke ^a   Heirman, Carlo ^a   Vanderkerken, Karin ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Conditional expression; IFN I; RNAi; shRNA design; shRNAmir; Tissue specific silencing

Indexed keywords

DNA DIRECTED RNA POLYMERASE; DNA DIRECTED RNA POLYMERASE III; DOUBLE STRANDED RNA; DOXYCYCLINE; ECDYSONE RECEPTOR; LENTIVIRUS VECTOR; MIFEPRISTONE; RETINOID X RECEPTOR; RNA POLYMERASE II; SHORT HAIRPIN RNA; TETRACYCLINE; TRANSFER RNA; SMALL INTERFERING RNA;

DRUG PROTEIN BINDING; GENE EXPRESSION; GENE TARGETING; GENETIC SCREENING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNE RESPONSE; NONHUMAN; PRACTICE GUIDELINE; PROMOTER REGION; REVIEW; VIRAL GENE DELIVERY SYSTEM; ANIMAL; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; LENTIVIRINAE; RNA INTERFERENCE;

ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 70349571162     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309788488578     Document Type: Review

References (260)

1. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263-7.
2. An DS, Morizono K, Li QX, Mao SH, Lu S, Chen IS. An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol 1999; 73(9): 7671-7.
3. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999; 283(5402): 682-6.
4. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73(4): 2886-92.
5. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72(12): 9873-80.
6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806-11.
7. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002; 13(18): 2197-201.
8. An DS, Xie Y, Mao SH, Morizono K, Kung SK, Chen IS. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 2003; 14(12): 1207-12.
9. Banerjea A, Li MJ, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8(1): 62-71.
10. Nishitsuji H, Ikeda T, Miyoshi H, Ohashi T, Kannagi M, Masuda T. Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect 2004; 6(1): 76-85.
11. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33(3): 401-6.
12. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003; 100(4): 1844-8.
13. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003; 2(3): 251-7.
14. Fountaine TM, Wood MJ, Wade-Martins R. Delivering RNA interference to the mammalian brain. Curr Gene Ther 2005; 5(4): 399-410.
15. Vilaboa N, Voellmy R. Regulatable gene expression systems for gene therapy. Curr Gene Ther 2006; 6(4): 421-38.
16. Yamamoto T, Tsunetsugu-Yokota Y. Prospects for the therapeutic application of lentivirus-based gene therapy to HIV-1 infection. Curr Gene Ther 2008; 8(1): 1-8.
17. Lee CC, Chiang BL. RNA interference: new therapeutics in allergic diseases. Curr Gene Ther 2008; 8(4): 236-46.
18. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007; 8(1): 23-36.
19. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15(2): 188-200.
20. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2(3): 243-7.
21. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296(5567): 550-3.
22. Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20(5): 500-5.
23. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20(5): 497-500.
24. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16(8): 948-58.
25. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 20(5): 505-8.
26. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494-8.
27. Amarzguioui M, Prydz H. An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 2004; 316(4): 1050-8.
28. Hsieh AC, Bo R, Manola J, et al. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res 2004; 32(3): 893-901.
29. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115(2): 209-16.
30. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22(3): 326-30.
31. Takasaki S, Kotani S, Konagaya A. An effective method for selecting siRNA target sequences in mammalian cells. Cell Cycle 2004; 3(6): 790-5.
32. Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32(3): 936-48.
33. Huesken D, Lange J, Mickanin C, et al. Design of a genome-wide siRNA library using an artificial neural network. Nat Biotechnol 2005; 23(8): 995-1001.
34. Li L, Lin X, Khvorova A, Fesik SW, Shen Y. Defining the optimal parameters for hairpin-based knockdown constructs. RNA 2007; 13(10): 1765-74.
35. Taxman DJ, Livingstone LR, Zhang J, et al. Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol 2006; 6: 7.
36. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21(6): 635-7.
37. Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005; 33(14): 4527-35.
38. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12(7): 1179-87.
39. Lai EC. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 2002; 30(4): 363-4.
40. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75(5): 855-62.
41. Birmingham A, Anderson EM, Reynolds A, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006; 3(3): 199-204.
42. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
43. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115(2): 199-208.
44. Brown KM, Chu CY, Rana TM. Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol 2005; 12(5): 469-70.
45. Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78(5): 2601-5.
46. Yoshinari K, Miyagishi M, Taira K. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res 2004; 32(2): 691-9.
47. Siolas D, Lerner C, Burchard J, et al. Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 2005; 23(2): 227-31.
48. Chu CY, Rana TM. Potent RNAi by short RNA triggers. RNA 2008; 14(9): 1714-9.
49. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005; 123(4): 631-40.
50. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23(2): 222-6.
51. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9(6): 1327-33.
52. McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA. Gene silencing using micro-RNA designed hairpins. RNA 2002; 8(6): 842-50.
53. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. Enhanced gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32(3): 1154-8.
54. Silva JM, Li MZ, Chang K, et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005; 37(11): 1281-8.
55. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37(11): 1289-95.
56. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102(37): 13212-7.
57. Liu YP, Haasnoot J, ter Brake O, Berkhout B, Konstantinova P. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008; 36(9): 2811-24.
58. Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008; 14(9): 1834-44.
59. Castanotto D, Sakurai K, Lingeman R, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 2007; 35(15): 5154-64.
60. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441(7092): 537-41.
61. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008; 105(15): 5868-73.
62. Paddison PJ, Cleary M, Silva JM, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods 2004; 1(2): 163-7.
63. Boden D, Pusch O, Lee F, Tucker L, Shank PR, Ramratnam B. Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res 2003; 31(17): 5033-8.
64. Kawasaki H, Taira K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 2003; 31(2): 700-7.
65. Myslinski E, Ame JC, Krol A, Carbon P. An unusually compact external promoter for RNA polymerase III transcription of the human H1RNA gene. Nucleic Acids Res 2001; 29(12): 2502-9.
66. Paule MR, White RJ. Survey and summary: transcription by RNA polymerases I and III. Nucleic Acids Res 2000; 28(6): 1283-98.
67. Matthess Y, Kappel S, Spankuch B, Zimmer B, Kaufmann M, Strebhardt K. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1. Oncogene 2005; 24(18): 2973-80.
68. Gunnery S, Ma Y, Mathews MB. Termination sequence requirements vary among genes transcribed by RNA polymerase III. J Mol Biol 1999; 286(3): 745-57.
69. Kleinert H, Benecke BJ. Transcription of human 7S K DNA in vitro and in vivo is exclusively controlled by an upstream promoter. Nucleic Acids Res 1988; 16(4): 1319-31.
70. Kunkel GR, Pederson T. Transcription of a human U6 small nuclear RNA gene in vivo withstands deletion of intragenic sequences but not of an upstream TATATA box. Nucleic Acids Res 1989; 17(18): 7371-9.
71. Schramm L, Hernandez N. Recruitment of RNA polymerase III to its target promoters. Genes Dev 2002; 16(20): 2593-620.
72. Geiduschek EP, Kassavetis GA. The RNA polymerase III transcription apparatus. J Mol Biol 2001; 310(1): 1-26.
73. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 2002; 99(8): 5515-20.
74. Yu JY, De Ruiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99(9): 6047-52.
75. Berget SM, Robberson BL. U1, U2, and U4/U6 small nuclear ribonucleoproteins are required for in vitro splicing but not polyadenylation. Cell 1986; 46(5): 691-6.
76. Guthrie C. Messenger RNA splicing in yeast: clues to why the spliceosome is a ribonucleoprotein. Science 1991; 253(5016): 157-63.
77. Surig D, Bredow S, Benecke BJ. The seemingly identical 7SK and U6 core promoters depend on different transcription factor complexes. Gene Expr 1993; 3(2): 175-85.
78. Makinen PI, Koponen JK, Karkkainen AM, et al. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 2006; 8(4): 433-41.
79. An DS, Qin FX, Auyeung VC, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther 2006; 14(4): 494-504.
80. Hasuwa H, Kaseda K, Einarsdottir T, Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett 2002; 532(1-2): 227-30.
81. Lambeth LS, Wise TG, Moore RJ, Muralitharan MS, Doran TJ. Comparison of bovine RNA polymerase III promoters for short hairpin RNA expression. Anim Genet 2006; 37(4): 369-72.
82. Koper-Emde D, Herrmann L, Sandrock B, Benecke BJ. RNA interference by small hairpin RNAs synthesised under control of the human 7S K RNA promoter. Biol Chem 2004; 385(9): 791-4.
83. Sotirova VN, Calciano MA, Krueger W, Lalande M. Inclusion of a matrix-attached region in a 7SK pol III vector increases the efficiency of shRNA-mediated gene silencing in embryonic carcinoma cells. Plasmid 2006; 55(3): 216-26.
84. Bannister SC, Wise TG, Cahill DM, Doran TJ. Comparison of chicken 7SK and U6 RNA polymerase III promoters for short hairpin RNA expression. BMC Biotechnol 2007; 7: 79.
85. Kudo T, Sutou S. Usage of putative chicken U6 promoters for vector-based RNA interference. JReprodDev 2005; 51(3): 411-7.
86. Noonberg SB, Scott GK, Benz CC. Evidence of post-transcriptional regulation of U6 small nuclear RNA. J Biol Chem 1996; 271(18): 10477-81.
87. Mangin M, Ares M, Jr., Weiner AM. U1 small nuclear RNA genes are subject to dosage compensation in mouse cells. Science 1985; 229(4710): 272-5.
88. Ilves H, Barske C, Junker U, Bohnlein E, Veres G. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene 1996; 171(2): 203-8.
89. Thompson JD, Ayers DF, Malmstrom TA, et al. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res 1995; 23(12): 2259-68.
90. Xia XG, Zhou H, Ding H, Affar eB, Shi Y, Xu Z. An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res 2003; 31(17): e100.
91. Ong ST, Li F, Du J, Tan YW, Wang S. Hybrid cytomegalovirus enhancer-h1 promoter-based plasmid and baculovirus vectors mediate effective RNA interference. Hum Gene Ther 2005; 16(12): 1404-12.
92. Hassani Z, Francois JC, Alfama G, et al. A hybrid CMV-H1 construct improves efficiency of PEI-delivered shRNA in the mouse brain. Nucleic Acids Res 2007; 35(9): e65.
93. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34(3): 263-4.
94. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20(10): 1006-10.
95. Denti MA, Rosa A, Sthandier O, De Angelis FG, Bozzoni I. A new vector, based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. Mol Ther 2004; 10(1): 191-9.
96. Michienzi A, Conti L, Varano B, Prislei S, Gessani S, Bozzoni I. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Hum Gene Ther 1998; 9(5): 621-8.
97. Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 2005; 33(6): e62.
98. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T. New microRNAs from mouse and human. RNA 2003; 9(2): 175-9.
99. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23(20): 4051-60.
100. Miyagishi M, Sumimoto H, Miyoshi H, Kawakami Y, Taira K. Optimization of an siRNA-expression system with an improved hairpin and its significant suppressive effects in mammalian cells. J Gene Med 2004; 6(7): 715-23.
101. Zeng Y, Cullen BR. Sequence requirements for micro RNA processing and function in human cells. RNA 2003; 9(1): 112-23.
102. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294(5543): 853-8.
103. Xia XG, Zhou H, Samper E, Melov S, Xu Z. Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice. PLoS Genet 2006; 2(1): e10.
104. Yuan J, Wang X, Zhang Y, et al. shRNA transcribed by RNA Pol II promoter induce RNA interference in mammalian cell. Mol Biol Rep 2006; 33(1): 43-9.
105. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16(9): 1630-6.
106. Brenz VMS, Weber P, Mayer C, et al. Development of a species-specific RNA polymerase I-based shRNA expression vector. Nucleic Acids Res 2007; 35(2): e10.
107. Grummt I. Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog Nucleic Acid Res Mol Biol 1999; 62: 109-54.
108. Heix J, Grummt I. Species specificity of transcription by RNA polymerase I. Curr Opin Genet Dev 1995; 5(5): 652-6.
109. Peng H, Callison D, Li P, Burrell C. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector. Virology 1996; 220(2): 377-89.
110. Peng H, Callison DE, Li P, Burrell CJ. Enhancement or inhibition of HIV-1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription. AIDS 1997; 11(5): 587-95.
111. Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication. Mol Cell Biol 1990; 10(12): 6512-23.
112. Yu M, Ojwang J, Yamada O, et al. A hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90(13): 6340-4.
113. Kawasaki H, Eckner R, Yao TP, et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 1998; 393(6682): 284-9.
114. Koseki S, Tanabe T, Tani K, et al. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J Virol 1999; 73(3): 1868-77.
115. Kuwabara T, Warashina M, Koseki S, et al. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucleic Acids Res 2001; 29(13): 2780-8.
116. Kuwabara T, Warashina M, Sano M, et al. Recognition of engineered tRNAs with an extended 3′ end by Exportin-t (Xpo-t) and transport of tRNA-attached ribozymes to the cytoplasm in somatic cells. Biomacromolecules 2001; 2(4): 1229-42.
117. Scherer LJ, Frank R, Rossi JJ. Optimization and characterization of tRNA-shRNA expression constructs. Nucleic Acids Res 2007; 35(8): 2620-8.
118. Watanabe T, Onuki R, Yamashita S, Taira K, Sugiyama Y. Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells. Pharm Res 2005; 22(8): 1287-93.
119. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequencespecific inhibition of small RNA function. PLoS Biol 2004; 2(4): E98.
120. Yi R, Doehle BP, Qin Y, Macara IG, Cullen BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 2005; 11(2): 220-6.
121. Devroe E, Silver PA. Retrovirus-delivered siRNA. BMC Biotechnol 2002; 2: 15.
122. Guo Y, Liu J, Li YH, et al. Effect of vector-expressed shRNAs on hTERT expression. World J Gastroenterol 2005; 11(19): 2912-5.
123. McIntyre GJ, Fanning GC. Design and cloning strategies for constructing shRNA expression vectors. BMC Biotechnol 2006; 6:1.
124. Kaykas A, Moon RT. A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol 2004; 5: 16.
125. Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 2004; 101(1): 135-40.
126. Jian R, Peng T, Deng S, et al. A simple strategy for generation of gene knockdown constructs with convergent H1 and U6 promoters. EurJCell Biol 2006; 85(5): 433-40.
127. Li MJ, McMahon R, Snyder DS, Yee JK, Rossi JJ. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/ abl small hairpin RNA. Oligonucleotides 2003; 13(5): 401-9.
128. Rossi JJ, Kierzek R, Huang T, Walker PA, Itakura K. An alternate method for synthesis of double-stranded DNA segments. J Biol Chem 1982; 257(16): 9226-9.
129. Unwalla HJ, Li MJ, Kim JD, et al. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol 2004; 22(12): 1573-8.
130. Zeng Y, Cai X, Cullen BR. Use of RNA polymerase II to transcribe artificial microRNAs. Methods Enzymol 2005; 392: 371-80.
131. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89(12): 5547-51.
132. Schnappinger D, Schubert P, Pfleiderer K, Hillen W. Determinants of protein-protein recognition by four helix bundles: changing the dimerization specificity of Tet repressor. EMBO J 1998; 17(2): 535-43.
133. Sprengel R, Hasan MT. Tetracycline-controlled genetic switches. Handb Exp Pharmacol 2007; (178): 49-72.
134. Robertson A, Perea J, Tolmachova T, Thomas PK, Huxley C. Effects of mouse strain, position of integration and tetracycline analogue on the tetracycline conditional system in transgenic mice. Gene 2002; 282(1-2): 65-74.
135. Ohkawa J, Taira K. Control of the functional activity of an antisense RNA by a tetracycline-responsive derivative of the human U6 snRNA promoter. HumGene Ther 2000; 11(4): 577-85.
136. Lin X, Yang J, Chen J, Gunasekera A, Fesik SW, Shen Y. Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett 2004; 577(3): 376-80.
137. Czauderna F, Santel A, Hinz M, et al. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003; 31(21): e127.
138. Henriksen JR, Lokke C, Hammero M, et al. Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines. Nucleic Acids Res 2007; 35(9): e67.
139. Kappel S, Matthess Y, Zimmer B, Kaufmann M, Strebhardt K. Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res 2006; 34(16): 4527-36.
140. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003; 31(15): e77.
141. van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003; 4(6): 609-15.
142. Dickins R, Hemann M, Zilfou J, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37(11): 1289-95.
143. Shin KJ, Wall E, Zavzavadjian J, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006; 103(37): 13759-64.
144. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97(14): 7963-8.
145. Qu Z, Thottassery JV, Van GS, et al. Homogeneity and long-term stability of tetracycline-regulated gene expression with low basal activity by using the rtTA2S-M2 transactivator and insulator-flanked reporter vectors. Gene 2004; 327(1): 61-73.
146. Das AT, Zhou X, Vink M, et al. Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 2004; 279(18): 18776-82.
147. Baron U, Gossen M, Bujard H. Tetracycline-controlled transcription in eukaryotes: novel transactivators with graded transactivation potential. Nucleic Acids Res 1997; 25(14): 2723-9.
148. Gill G, Ptashne M. Negative effect of the transcriptional activator GAL4. Nature 1988; 334(6184): 721-4.
149. Amar L, Desclaux M, Faucon-Biguet N, Mallet J, Vogel R. Control of small inhibitory RNA levels and RNA interference by doxycycline induced activation of a minimal RNA polymerase III promoter. Nucleic Acids Res 2006; 34(5): e37.
150. Tanaka M, Lai JS, Herr W. Promoter-selective activation domains in Oct-1 and Oct-2 direct differential activation of an snRNA and mRNA promoter. Cell 1992; 68(4): 755-67.
151. Fei Z, Chen Z, Wang Z, Fei J. Conditional RNA interference achieved by Oct-1 POU/rtTA fusion protein activator and a modified TRE-mouse U6 promoter. Biochem Biophys Res Commun 2007; 354(4): 906-12.
152. Anastassiadis K, Kim J, Daigle N, Sprengel R, Scholer HR, Stewart AF. A predictable ligand regulated expression strategy for stably integrated transgenes in mammalian cells in culture. Gene 2002; 298(2): 159-72.
153. Bohner S, Lenk II, Rieping M, Herold M, Gatz C. Technical advance: transcriptional activator TGV mediates dexamethasone-inducible and tetracycline-inactivatable gene expression. Plant J 1999; 19(1): 87-95.
154. Iida A, Chen ST, Friedmann T, Yee JK. Inducible gene expression by retrovirus-mediated transfer of a modified tetracycline-regulated system. J Virol 1996; 70(9): 6054-9.
155. Szulc J, Wiznerowicz M, Sauvain MO, Trono D, Aebischer P. A versatile tool for conditional gene expression and knockdown. NatMethods 2006; 3(2): 109-16.
156. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. JVirol 2003; 77(16): 8957-61.
157. Bellefroid EJ, Poncelet DA, Lecocq PJ, Revelant O, Martial JA. The evolutionarily conserved Kruppel-associated box domain defines a subfamily of eukaryotic multifingered proteins. Proc Natl Acad Sci USA 1991; 88(9): 3608-12.
158. Deuschle U, Meyer WK, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995; 15(4): 1907-14.
159. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ, Rauscher FJ, 3rd. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA 1994; 91(10): 4509-13.
160. Moosmann P, Georgiev O, Thiesen HJ, Hagmann M, Schaffner W. Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Kruppel-type zinc finger factor. Biol Chem 1997; 378(7): 669-77.
161. Senatore B, Cafieri A, Di Marino I, Rosati M, Di Nocera PP, Grimaldi G. A variety of RNA polymerases II and III-dependent promoter classes is repressed by factors containing the Kruppel-associated/finger preceding box of zinc finger proteins. Gene 1999; 234(2): 381-94.
162. Wiznerowicz M, Szulc J, Trono D. Tuning silence: conditional systems for RNA interference. Nat Methods 2006; 3(9): 682-8.
163. Bell CE, Lewis M. A closer view of the conformation of the Lac repressor bound to operator. Nat Struct Biol 2000; 7(3): 209-14.
164. Bell CE, Lewis M. The Lac repressor: a second generation of structural and functional studies. Curr Opin Struct Biol 2001; 11(1): 19-25.
165. Lewis M, Chang G, Horton NC, et al. Crystal structure of the lactose operon repressor and its complexes with DNA and inducer. Science 1996; 271(5253): 1247-54.
166. Higuchi M, Tsutsumi R, Higashi H, Hatakeyama M. Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity. Cancer Sci 2004; 95(5): 442-7.
167. Wu RH, Cheng TL, Lo SR, et al. A tightly regulated and reversibly inducible siRNA expression system for conditional RNAi-mediated gene silencing in mammalian cells. J Gene Med 2007; 9(7): 620-34.
168. Sadler JR, Sasmor H, Betz JL. A perfectly symmetric lac operator binds the lac repressor very tightly. Proc Natl Acad Sci USA 1983; 80(22): 6785-9.
169. Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 2004; 101(7): 1927-32.
170. Das G, Hinkley CS, Herr W. Basal promoter elements as a selective determinant of transcriptional activator function. Nature 1995; 374(6523): 657-60.
171. Rangasamy D, Greaves I, Tremethick DJ. RNA interference demonstrates a novel role for H2A.Z in chromosome segregation. Nat Struct Mol Biol 2004; 11(7): 650-5.
172. Rangasamy D, Tremethick DJ, Greaves IK. Gene knockdown by ecdysone-based inducible RNAi in stable mammalian cell lines. Nat Protoc 2008; 3(1): 79-88.
173. Greaves IK, Rangasamy D, Ridgway P, Tremethick DJ. H2A.Z contributes to the unique 3D structure of the centromere. Proc Natl Acad Sci USA 2007; 104(2): 525-30.
174. Peng Y, Lu JX, Shen XF. shRNA driven by Pol II/T7 dual-promoter system effectively induce cell-specific RNA interference in mammalian cells. Biochem Biophys Res Commun 2007; 360(2): 496-500.
175. Huang M, Jia FJ, Yan YC, Guo LH, Li YP. Transactivated minimal E1b promoter is capable of driving the expression of short hairpin RNA. J Virol Methods 2006; 134(1-2): 48-54.
176. Koster RW, Fraser SE. Tracing transgene expression in living zebrafish embryos. Dev Biol 2001; 233(2): 329-46.
177. An CI, Trinh VB, Yokobayashi Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA 2006; 12(5): 710-6.
178. Jenison RD, Gill SC, Pardi A, Polisky B. High-resolution molecular discrimination by RNA. Science 1994; 263(5152): 1425-9.
179. Zimmermann GR, Jenison RD, Wick CL, Simorre JP, Pardi A. Interlocking structural motifs mediate molecular discrimination by a theophylline-binding RNA. Nat Struct Biol 1997; 4(8): 644-9.
180. Sternberg N, Sauer B, Hoess R, Abremski K. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. J Mol Biol 1986; 187(2): 197-212.
181. Hoess R, Abremski K, Irwin S, Kendall M, Mack A. DNA specificity of the Cre recombinase resides in the 25 kDa carboxyl domain of the protein. J Mol Biol 1990; 216(4): 873-82.
182. Gagneten S, Le Y, Miller J, Sauer B. Brief expression of a GFP cre fusion gene in embryonic stem cells allows rapid retrieval of site-specific genomic deletions. Nucleic Acids Res 1997; 25(16): 3326-31.
183. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F. Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes. Proc Natl Acad Sci U S A 2002; 99(7): 4489-94.
184. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55(6): 1189-93.
185. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55(6): 1179-88.
186. Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods 1998; 14(4): 381-92.
187. Abremski K, Hoess R, Sternberg N. Studies on the properties of P1 site-specific recombination: evidence for topologically unlinked products following recombination. Cell 1983; 32(4): 1301-11.
188. Nagy A, Mar L. Creation and use of a Cre recombinase transgenic database. Methods Mol Biol 2001; 158: 95-106.
189. Coumoul X, Li W, Wang RH, Deng C. Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system. Nucleic Acids Res 2004; 32(10): e85.
190. Fritsch L, Martinez LA, Sekhri R, et al i. Conditional gene knock-down by CRE-dependent short interfering RNAs. EMBO Rep 2004; 5(2): 178-82.
191. Tiscornia G, Tergaonkar V, Galimi F, Verma IM. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci USA 2004; 101(19): 7347-51.
192. Ventura A, Meissner A, Dillon CP, et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101(28): 10380-5.
193. Iovino N, Denti MA, Bozzoni I, Cortese R. A loxP-containing pol II promoter for RNA interference is reversibly regulated by Cre recombinase. RNA Biol 2005; 2(3): 86-92.
194. Kasim V, Miyagishi M, Taira K. Control of siRNA expression using the Cre-loxP recombination system. Nucleic Acids Res 2004; 32(7): e66.
195. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
196. Steuber-Buchberger P, Wurst W, Kuhn R. Simultaneous Cremediated conditional knockdown of two genes in mice. Genesis 2008; 46(3): 144-51.
197. Coumoul X, Shukla V, Li C, Wang RH, Deng CX. Conditional knockdown of Fgfr2 in mice using Cre-LoxP induced RNA interference. Nucleic Acids Res 2005; 33(11): e102.
198. Heinonen JE, Mohamed AJ, Nore BF, Smith CI. Inducible H1 promoter-driven lentiviral siRNA expression by Stuffer reporter deletion. Oligonucleotides 2005; 15(2): 139-44.
199. Metzger D, Clifford J, Chiba H, Chambon P. Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci USA 1995; 92(15): 6991-5.
200. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P. Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 1996; 93(20): 10887-90.
201. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG. Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 1993; 7(2): 232-40.
202. Feil R, Wagner J, Metzger D, Chambon P. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 1997; 237(3): 752-7.
203. Brown BD, Gentner B, Cantore A, et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 2007; 25(12): 1457-67.
204. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12(5): 585-91.
205. Konstantinova P, de Vries W, Haasnoot J, ter Brake O, de Haan P, Berkhout B. Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther 2006; 13(19): 1403-13.
206. Liu YP, Haasnoot J, Berkhout B. Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res 2007; 35(17): 5683-93.
207. Henry SD, van der WP, Metselaar HJ, Tilanus HW, Scholte BJ, van der Laan LJ. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther 2006; 14(4): 485-93.
208. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14(6): 883-92.
209. Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/ miR-155. Nucleic Acids Res 2006; 34(7): e53.
210. Gonzalez S, Castanotto D, Li H, et al. Amplification of RNAi - targeting HLA mRNAs. Mol Ther 2005; 11(5): 811-8.
211. Song J, Giang A, Lu Y, Pang S, Chiu R. Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep 2008; 41(5): 358-62.
212. Hung CF, Cheng TL, Wu RH, Teng CF, Chang WT. A novel bidirectional expression system for simultaneous expression of both the protein-coding genes and short hairpin RNAs in mammalian cells. Biochem Biophys Res Commun 2006; 339(4): 1035-42.
213. Jazag A, Kanai F, Ijichi H, et al. Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res 2005; 33(15): e131.
214. Schuck S, Manninen A, Honsho M, Fullekrug J, Simons K. Generation of single and double knockdowns in polarized epithelial cells by retrovirus-mediated RNA interference. Proc Natl Acad Sci U S A 2004; 101(14): 4912-7.
215. Nagao A, Zhao X, Takegami T, et al. Multiple shRNA expressions in a single plasmid vector improve RNAi against the XPA gene. Biochem Biophys Res Commun 2008; 370(2): 301-5.
216. Schubert S, Grunert HP, Zeichhardt H, Werk D, Erdmann VA, Kurreck J. Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. J Mol Biol 2005; 346(2): 457-65.
217. Sumimoto H, Hirata K, Yamagata S, et al. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. Int J Cancer 2006; 118(2): 472-6.
218. Ter Brake O, Hooft KT, Liu YP, Centlivre M, Jasmijn von Eije K, Berkhout B. Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition. Mol Ther 2008; 16(3): 557-64.
219. Gou D, Weng T, Wang Y, et al. A novel approach for the construction of multiple shRNA expression vectors. J Gene Med 2007; 9(9): 751-63.
220. Rumi M, Ishihara S, Aziz M, et al. RNA polymerase II mediated transcription from the polymerase III promoters in short hairpin RNA expression vector. Biochem Biophys Res Commun 2006; 339(2): 540-7.
221. Shin KJ, Wall EA, Zavzavadjian JR, et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci USA 2006; 103(37): 13759-64.
222. Zhu X, Santat LA, Chang MS, et al. A versatile approach to multiple gene RNA interference using microRNA-based short hairpin RNAs. BMC Mol Biol 2007; 8:98.
223. Sun D, Melegari M, Sridhar S, Rogler CE, Zhu L. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques 2006; 41(1): 59-63.
224. Xia XG, Zhou H, Xu Z. Multiple shRNAs expressed by an inducible pol II promoter can knock down the expression of multiple target genes. Biotechniques 2006; 41(1): 64-8.
225. Niu QW, Lin SS, Reyes JL, et al. Expression of artificial microRNAs in transgenic Arabidopsis thaliana confers virus resistance. Nat Biotechnol 2006; 24(11): 1420-8.
226. Aagaard L, Zhang J, von Eije KJ, et al. Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther 2008; 15(23): 1566.
227. Shan G, Li Y, Zhang J, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008; 26(8): 933-40.
228. Bhanot SK, Singh M, Chatterjee NR. The chemical and biological aspects of fluoroquinolones: reality and dreams. Curr Pharm Des 2001; 7(5): 311-35.
229. Nagasaki A, Kanada M, Uyeda TQ. A novel shRNA vector that enables rapid selection and identification of knockdown cells. Plasmid 2007; 58(2): 190-4.
230. Izumi M, Miyazawa H, Kamakura T, Yamaguchi I, Endo T, Hanaoka F. Blasticidin S-resistance gene (bsr): a novel selectable marker for mammalian cells. Exp Cell Res 1991; 197(2): 229-33.
231. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6(7): 821-5.
232. Gantier MP, Williams BR. The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 2007; 18(5-6): 363-71.
233. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001; 55: 255-81.
234. Wang Q, Carmichael GG. Effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev 2004; 68(3): 432-52.
235. Manche L, Green SR, Schmedt C, Mathews MB. Interactions between double-stranded RNA regulators and the protein kinase DAI. Mol Cell Biol 1992; 12(11): 5238-48.
236. Samuel CE. Mechanism of interferon action: phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase. Proc Natl Acad Sci U S A 1979; 76(2): 600-4.
237. Hartmann R, Justesen J, Sarkar SN, Sen GC, Yee VC. Crystal structure of the 2′-specific and double-stranded RNA-activated interferon-induced antiviral protein 2′-5′-oligoadenylate synthetase. Mol Cell 2003; 12(5): 1173-85.
238. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 1993; 12(8): 3297-304.
239. Kato H, Sato S, Yoneyama M, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005; 23(1): 19-28.
240. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19(6): 727-40.
241. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5(7): 730-7.
242. Karpala AJ, Doran TJ, Bean AG. Immune responses to dsRNA: implications for gene silencing technologies. Immunol Cell Biol 2005; 83(3): 211-6.
243. Watanabe T, Sudoh M, Miyagishi M, et al. Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther 2006; 13(11): 883-92.
244. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5(9): 834-9.
245. Saunders LR, Barber GN. The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 2003; 17(9): 961-83.
246. Marques JT, Devosse T, Wang D, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 2006; 24(5): 559-65.
247. Pebernard S, Iggo RD. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 2004; 72(2-3): 103-11.
248. Kariko K, Bhuyan P, Capodici J, Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 2004; 172(11): 6545-9.
249. Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 2004; 10(1): 12-8.
250. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A 2003; 100(11): 6347-52.
251. Sioud M. Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348(5): 1079-90.
252. Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312(4): 1220-5.
253. Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequencespecific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. NatMed 2005; 11(3): 263-70.
254. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17(1): 1-14.
255. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23(4): 457-62.
256. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 2004; 22(3): 321-5.
257. Gondai T, Yamaguchi K, Miyano-Kurosaki N, Habu Y, Takaku H. Short-hairpin RNAs synthesized by T7 phage polymerase do not induce interferon. Nucleic Acids Res 2008; 36(3): e18.
258. Robbins MA, Li M, Leung I, et al. Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006; 24(5): 566-71.
259. Bauer M, Kinkl N, Meixner A, et al. Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther 2009; 16(1): 142-7.
260. Cullen BR. Induction of stable RNA interference in mammalian cells. Gene Ther 2006; 13(6): 503-8.